Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Equity Average (2016 - 2025)

Arrowhead Pharmaceuticals' Equity Average history spans 15 years, with the latest figure at $535.9 million for Q4 2025.

  • For Q4 2025, Equity Average rose 333.7% year-over-year to $535.9 million; the TTM value through Dec 2025 reached $535.9 million, up 333.7%, while the annual FY2025 figure was $347.2 million, 45.22% up from the prior year.
  • Equity Average reached $535.9 million in Q4 2025 per ARWR's latest filing, up from $512.9 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $603.3 million in Q2 2025 to a low of $123.6 million in Q4 2024.
  • Average Equity Average over 5 years is $400.8 million, with a median of $420.0 million recorded in 2021.
  • Peak YoY movement for Equity Average: crashed 46.38% in 2024, then skyrocketed 333.7% in 2025.
  • A 5-year view of Equity Average shows it stood at $390.7 million in 2021, then increased by 4.27% to $407.4 million in 2022, then tumbled by 43.43% to $230.4 million in 2023, then plummeted by 46.38% to $123.6 million in 2024, then surged by 333.7% to $535.9 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Equity Average are $535.9 million (Q4 2025), $512.9 million (Q3 2025), and $603.3 million (Q2 2025).